Metvix

Methyl aminolevulinate, the active ingredient in Metvix, is a photosensitizing agent presented as a 16% w/w cream for topical use. It is used to treat actinic keratosis, a precancerous skin condition, in adult patients with field cancerization.

GNH USA supplies Metvix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metvix is employed in photodynamic therapy for actinic keratosis, a field of dysplastic skin lesions.

Actinic keratosis (field cancerization): reduces dysplastic keratinocytes and improves the appearance of the treated skin area.

Metvix may cause local skin reactions following illumination.

Common Side Effects: - Erythema: redness at the treatment site. - Edema: mild swelling of the skin. - Pain or burning sensation during or after illumination. - Crusting or scaling of the treated area. - Itching or pruritus. - Transient hyperpigmentation.

Serious or Rare Side Effects: - Severe photosensitivity reactions extending beyond the treated field. - Allergic dermatitis or urticaria. - Secondary infection of the treated skin. - Persistent scarring or hypopigmentation. - Systemic absorption leading to hemolysis in susceptible individuals.

Before using Metvix, consider the following safety measures.

Sun exposure: avoid direct sunlight on treated areas for at least 48 hours after illumination. Application site: ensure skin is clean, free of open wounds, and dry before applying the cream. Pregnancy and lactation: safety is unknown; use only if the potential benefit justifies the risk. Concomitant photosensitizers: avoid using other photosensitizing drugs or topical agents that may increase phototoxicity. Hypersensitivity: discontinue use if a severe allergic reaction occurs. Store at room temperature: keep the cream in the original container, protect from light and moisture, and store below 25 °C.

Metvix can interact with other agents that affect photosensitivity or skin healing.

Major Interactions (Avoid): - Systemic photosensitizing drugs (e.g., tetracyclines, sulfonamides) may amplify phototoxic reactions. - Concurrent use of other photodynamic therapy agents can lead to overlapping toxicity. - Porphyrin‑related compounds that increase systemic porphyrin levels.

Moderate Interactions (Monitor Closely): - Topical corticosteroids may reduce the efficacy of photodynamic therapy. - Systemic immunosuppressants could delay wound healing after treatment. - Other dermatologic topical agents (e.g., retinoids) should be timed to avoid interference with illumination.